IgE-ОТВЕТ ПОСЛЕ ВВЕДЕНИЯ ПАНДЕМИЧЕСКОЙ ВАКЦИНЫ ШТАММА А/CALIFORNIA/7/2009 (Н1N1)v

Changes in total and allergy-specific IgE (IgE-antibodies) in 70 healthy volunteers vaccinated with influenza vaccine subunit strain A/California/7/2009/(H1N1). Safety of this vaccine was shown. Repeated second dose administration is not accompanied by increase in IgE-antibodies to egg components. Vaccine injection results in decrease of total IgE in patients with elevated IgE at baseline. В статье представлена оценка изменения общих и аллергоспецифических IgE-антител у 70 здоровых волонтеров, привитых вакциной гриппозной субъединичной, штамм А/California/7/2009/(H1N1). Показано, что вакцина безопасна. Установлено, что двукратное введение вакцины не сопровождается нарастанием титра IgE-антител к тканевым компонентам куриного яйца. Также отмечено, что введение препарата сопровождается снижением общего IgE у лиц с исходно повышенным показателем.

Post-vaccination immunity to pneumococcal, haemophilus influenzae type B infection and influenza in patients with chronic obstructive pulmonary disease (COPD)

Background: The goal of the present work was to study the dynamics of antibodies production to S. pneumoniae, H. influenzae type b, influenza virus strains A/H1N1, A/H3N2 and B after combined vaccination of patients with chronic obstructive pulmonary disease (COPD) considering the severity of the disease. Methods: To evaluate the dynamics of vaccination process (before vaccination and 3, 6 and 12 months later) 128 patients suffering from COPD, aged 45-80 years and with different severity of disease were examined. Group 1 (n=48), which was concomitantly vaccinated by Pneumo 23, Hiberix and Grippol Plus beyond the period of exacerbation in course of the standard therapy of COPD. Group 2 (n=80) nonvaccinated patients with COPD. Results: Combined vaccination against pneumococcal, H. influenzae type b and influenza is accompanied by production of antibodies to these infections, which persist during one year (observation period), regardless of disease severity. In patients with stage 4 COPD the level of antibodies to influenza virus in post-vaccination period was lower than in patients with stages 1, 2 and 3. Probably, these patients should be vaccinated against influenza twice. Despite the fact that patients with COPD had lower levels of post-vaccination antibodies than control, they demonstrated apparent clinical effect throughout 12 months, which was recorded as reduction of both exacerbation number in 3.7 times and the need in antibacterial medications in 4.3 times. Conclusion: Combined vaccination against bacterial and viral infections contributes to the achievement of antibody levels leading to development of significant clinical effect in patients with COPD. © 2014 Pakhomov DV, et al

Immunogenicity and safety of the quadrivalent adjuvant subunit influenza vaccine in seropositive and seronegative healthy people and patients with common variable immunodeficiency

Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018–2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used. Results. All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels. Conclusion. Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies’ presence or absence before. In CVID patients search of new regimens should be continued. © 2020 by the authors. Licensee MDPI, Basel, Switzerland

IgE-response after administration of pandemic vaccine strain A/California/7/2009 (H1N1) v

Changes in total and allergy-specific IgE (IgE-antibodies) in 70 healthy volunteers vaccinated with influenza vaccine subunit strain A/California/7/2009/ (H1N1) v. Safety of this vaccine was shown. Repeated second dose administration is not accompanied by increase in IgE-antibodies to egg components. Vaccine injection results in decrease of total IgE in patients with elevated IgE at baseline

CLINICAL AND IMMUNOLOGICAL EFFECT OF PNEUMOCOCCAL CONJUGATED VACCINES IN IMMUNOCOMPROMISED PATIENTS

Invasive pneumococcal infection is the most frequent cause of death in patients with immunodeficiences. The antibiotics used previously for prevention purposes are not efficient enough due to the developing antibiotic resistance. Polysaccharide pneumococcal vaccines create short-lived immunity. The overview summarizes the experience of applying conjugated pneumococcal vaccines in patients with primary immunodeficiences, HIV infection, oncological and rheumatic diseases. Key words: pneumococcal infection, pneumococcal conjugated vaccines, children, immunosuppression. (Pediatric Pharmacology. – 2010; 7(5):18-23

CLINICAL AND IMMUNOLOGICAL EFFECT OF PNEUMOCOCCAL CONJUGATED VACCINES IN IMMUNOCOMPROMISED PATIENTS

Invasive pneumococcal infection is the most frequent cause of death in patients with immunodeficiences. The antibiotics used previously for prevention purposes are not efficient enough due to the developing antibiotic resistance. Polysaccharide pneumococcal vaccines create short-lived immunity. The overview summarizes the experience of applying conjugated pneumococcal vaccines in patients with primary immunodeficiences, HIV infection, oncological and rheumatic diseases. Key words: pneumococcal infection, pneumococcal conjugated vaccines, children, immunosuppression. (Pediatric Pharmacology. – 2010; 7(5):18-23

PROPHYLAXIS OF PNEUMOCOCCAL INFECTION WITH VACCINES FOR PREVENTION OF COMPLICATIONS AND DEATH IN PATIENTS WITH INFLUENZA

The article analyzes the role of pneumococcal infection as a cause of complications and death in patients with influenza. Authors performed historic analysis of data on development of bacterial complications in period of influenza pandemic. Possible pathogenetic mechanisms of bacterial co-infection development are characterizeed. Effective vaccination of children with pneumococcal conjugated vaccine is able to decrease morbidity and mortality in common population and in group of high risk patients.Key words: children, pneumococcal infection, influenza, complications, mortality, vaccination.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(6):131-134

FACTS AND OPINIONS ON USEFULNESS OF PNEUMOCOCCAL VACCINE

The article describes the problem of pneumococcal infections (pneumonias, meningitis, otitis) in children and adults. The modern opportunities of vaccinoprophylaxis and its usefulness in public health service are shown. The perspectives and questions on safety and effectiveness of pneumococcal conjugated 7-valent vaccine as the basic method of pneumococcal infections prophylaxis in infants and children from risk groups (with bronchial asthma, sickle-cell anemia, etc.) are presented in details.Key words: children, pneumococcal infection, vaccination, pneumococcal conjugated 7-valent vaccine.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(4):79-83)</span

КЛИНИЧЕСКИЙ И ИММУНОЛОГИЧЕСКИЙ ЭФФЕКТ ПНЕВМОКОККОВЫХ КОНЪЮГИРОВАННЫХ ВАКЦИН У ИММУНОКОМПРОМЕТИРОВАННЫХ ПАЦИЕНТОВ

Invasive pneumococcal infection is the most frequent cause of death in patients with immunodeficiences. The antibiotics used previously for prevention purposes are not efficient enough due to the developing antibiotic resistance. Polysaccharide pneumococcal vaccines create short-lived immunity. The overview summarizes the experience of applying conjugated pneumococcal vaccines in patients with primary immunodeficiences, HIV infection, oncological and rheumatic diseases. Key words: pneumococcal infection, pneumococcal conjugated vaccines, children, immunosuppression. (Pediatric Pharmacology. – 2010; 7(5):18-23)Инвазивная пневмококковая инфекция наиболее часто является причиной смерти у пациентов с иммунодефицитами. Применявшиеся ранее для профилактики антибиотики недостаточно эффективны в связи с развитием антибиотикорезистентности. Полисахаридные пневмококковые вакцины создают непродолжительный иммунитет. В обзоре обобщен опыт применения конъюгированных пневмококковых вакцин у пациентов с первичными иммунодефицитами, ВИЧ-инфекцией, онкологическими и ревматическими болезнями. Ключевые слова: пневмококковая инфекция, пневмококковые конъюгированные вакцины, дети, иммуносупрессия. (Педиатрическая фармакология. – 2010; 7(5): 18-23

PROGNOSTICATION OF VACCINATION EFFICACY

The article focuses on the study of protective immunity in vaccination with pneumococcal conjugated 7-valent vaccine (PCV7) against related vaccine serotypes. It provides results of a study which compared the opsonization capability of all vaccine serotypes with that of two related serotypes (6A and 19A) to analyse immune response. The study results showed that functional cross immunity to serotype 19A after vaccination with conjugated vaccine that does not contain polysaccharide of this serotype is virtually non-existent. Key words: invasive pneumococcal infections, pneumococcal conjugated 7-valent vaccine, children, related vaccine serotypes, opsonophagocytic activity. (Pediatric Pharmacology. – 2010; 7(2):36-40